Intravitreal Brolucizumab for Choroidal Neovascularization Associated to Angioid Streaks
A 44-year-old-female with angioid streak- (AS-) associated choroidal-neovascularization (CNV) was treated with one dose of intravitreal brolucizumab (IB). At one-month, the patient’s visual acuity (VA) improved from 20/120 to 20/40 with a dry macula on spectral-domain optical-coherence tomography (S...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Case Reports in Ophthalmological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2022/3442306 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832558362630291456 |
|---|---|
| author | Somnath Chakraborty Jay Umed Sheth |
| author_facet | Somnath Chakraborty Jay Umed Sheth |
| author_sort | Somnath Chakraborty |
| collection | DOAJ |
| description | A 44-year-old-female with angioid streak- (AS-) associated choroidal-neovascularization (CNV) was treated with one dose of intravitreal brolucizumab (IB). At one-month, the patient’s visual acuity (VA) improved from 20/120 to 20/40 with a dry macula on spectral-domain optical-coherence tomography (SD-OCT). After observation, the VA improved further to 20/32 with absence of any fluid on the SD-OCT at three months. No ocular or systemic adverse events were noted. In conclusion, intravitreal brolucizumab (IB) is an efficacious and safe therapeutic option for the management of CNV secondary to AS. Further prospective studies with a larger sample size, varied therapeutic regimens, and longer follow-up period are needed to corroborate our findings. |
| format | Article |
| id | doaj-art-0a624c39987a4429885eeae26c17618d |
| institution | Kabale University |
| issn | 2090-6730 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Ophthalmological Medicine |
| spelling | doaj-art-0a624c39987a4429885eeae26c17618d2025-02-03T01:32:26ZengWileyCase Reports in Ophthalmological Medicine2090-67302022-01-01202210.1155/2022/3442306Intravitreal Brolucizumab for Choroidal Neovascularization Associated to Angioid StreaksSomnath Chakraborty0Jay Umed Sheth1Retina Institute of BengalSurya Eye Institute and Research CenterA 44-year-old-female with angioid streak- (AS-) associated choroidal-neovascularization (CNV) was treated with one dose of intravitreal brolucizumab (IB). At one-month, the patient’s visual acuity (VA) improved from 20/120 to 20/40 with a dry macula on spectral-domain optical-coherence tomography (SD-OCT). After observation, the VA improved further to 20/32 with absence of any fluid on the SD-OCT at three months. No ocular or systemic adverse events were noted. In conclusion, intravitreal brolucizumab (IB) is an efficacious and safe therapeutic option for the management of CNV secondary to AS. Further prospective studies with a larger sample size, varied therapeutic regimens, and longer follow-up period are needed to corroborate our findings.http://dx.doi.org/10.1155/2022/3442306 |
| spellingShingle | Somnath Chakraborty Jay Umed Sheth Intravitreal Brolucizumab for Choroidal Neovascularization Associated to Angioid Streaks Case Reports in Ophthalmological Medicine |
| title | Intravitreal Brolucizumab for Choroidal Neovascularization Associated to Angioid Streaks |
| title_full | Intravitreal Brolucizumab for Choroidal Neovascularization Associated to Angioid Streaks |
| title_fullStr | Intravitreal Brolucizumab for Choroidal Neovascularization Associated to Angioid Streaks |
| title_full_unstemmed | Intravitreal Brolucizumab for Choroidal Neovascularization Associated to Angioid Streaks |
| title_short | Intravitreal Brolucizumab for Choroidal Neovascularization Associated to Angioid Streaks |
| title_sort | intravitreal brolucizumab for choroidal neovascularization associated to angioid streaks |
| url | http://dx.doi.org/10.1155/2022/3442306 |
| work_keys_str_mv | AT somnathchakraborty intravitrealbrolucizumabforchoroidalneovascularizationassociatedtoangioidstreaks AT jayumedsheth intravitrealbrolucizumabforchoroidalneovascularizationassociatedtoangioidstreaks |